Valuation: argenx SE

Market Cap 60.06B 52.82B 49.95B 45.3B 85.08B 5,765B 85.57B 598B 231B 2,942B 225B 221B 9,453B P/E 2026 *
31.2x
P/E 2027 * 25.6x
Enterprise Value 56.35B 49.56B 46.87B 42.51B 79.83B 5,409B 80.3B 561B 217B 2,760B 212B 207B 8,870B EV / Sales 2026 *
8.99x
EV / Sales 2027 * 7.07x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.08%
1 day-0.07%
1 week-2.70%
Current month-3.54%
1 month-5.65%
3 months+7.67%
6 months+39.05%
Current year+17.83%
1 week 826
Extreme 826
861.6
1 month 826
Extreme 826
925
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-2.70%+37.74%+86.90% 60.24B
-0.37%-3.67%+57.21%+87.75% 72.26B
+3.65%+5.41%+40.15%+21.58% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-7.59% 20.74B
-1.70%+0.43%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
+4.39%-3.30%-4.36%+518.80% 14.23B
-0.83%-8.40%-26.11%+745.90% 12.45B
Average +0.70%-0.94%+31.63%+229.11% 28.76B
Weighted average by Cap. +0.48%-1.39%+35.78%+156.39%

Financials

2026 *2027 *
Net sales 6.27B 5.51B 5.21B 4.73B 8.88B 601B 8.93B 62.39B 24.1B 307B 23.52B 23.02B 986B 7.62B 6.7B 6.34B 5.75B 10.8B 732B 10.86B 75.9B 29.31B 373B 28.62B 28B 1,200B
Net income 1.14B 1.01B 951M 862M 1.62B 110B 1.63B 11.38B 4.4B 56B 4.29B 4.2B 180B 2.39B 2.1B 1.99B 1.8B 3.39B 230B 3.41B 23.81B 9.2B 117B 8.98B 8.78B 376B
Net Debt -3.7B -3.26B -3.08B -2.79B -5.25B -356B -5.28B -36.88B -14.24B -181B -13.91B -13.6B -583B -6.19B -5.44B -5.14B -4.67B -8.76B -594B -8.81B -61.59B -23.79B -303B -23.22B -22.72B -974B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-09-28 €844.60 -0.07% 50,685
26-09-25 €845.20 +1.25% 55,346
26-09-24 €834.80 -0.12% 57,242
26-09-23 €835.80 -2.29% 80,913
26-09-22 €855.40 -1.45% 60,546
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
960.32USD
Average target price
1,175.30USD
Spread / Average Target
+22.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock